Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
University of California, San Diego
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Abramson Cancer Center at Penn Medicine
Five Prime Therapeutics, Inc.
Bristol-Myers Squibb